All biopsy samples were stained with hematoxylin & eosin and giemsa in Pathology Department by a pathologist, 3-deazaneplanocin A nmr who was blinded to the treatment arm. The result of RUT was defined positive if the color of the gel turned pink or red 6 hours after examination. Of the 120 patients,
77 underwent endoscopy and were diagnosed by using RUT and/or histological evaluation (64.1%), and 43 were diagnosed by UBT (35.9%). Endoscopy was performed by the discretion of the managing physician. A trained interviewer obtained demographic data and filled a standardized questionnaire. The participants were randomly assigned into two groups to receive OBAG or OBAC. The former group received omeprazole (20 mg) twice daily, bismuth subcitrate (240 mg) twice daily,
amoxicillin (1 gr) twice daily, and gemifloxacin (320 mg) once daily for 10 days, and the latter group received omeprazole (20 mg) twice daily, bismuth subcitrate (240 mg) twice daily, amoxicillin (1 gr) twice daily, and clarithromycin (500 mg) twice daily for 10 days. The participants were requested to refer again to the clinic during the second week to evaluate their compliance, as well as adverse drug effects. Compliance was Ro3280 acceptable when over 80% of the total medications were taken. The adverse effects included anorexia, nausea, vomiting, headache, skin rash, and bitter mouth. All the participants underwent UBT 8 weeks after completion of treatment to confirm H.pylori eradication. Gender distribution as well as the efficacy and frequency of side effects Erastin cell line in the two groups were compared by Chi-square test. Data analysis was performed on both per protocol (PP) and intention-to-treat (ITT) bases.
A p-value<0.05 was considered as statistically significant. Statistical analyses were performed using the SPSS software (version18; SPSS Inc.). This study was approved by both the Deputy Research of Iran University of Medical Sciences and Colorectal Research Center at Rasoul-e-Akram General Hospital, Tehran, Iran. RESULTS A total of 120 patients were enrolled in the study, and randomly assigned into OBAG (n=60) or OBAC (n=60) groups. Five patients from each group were excluded from the study because of poor compliance. Both groups had similar compliance according to the number of pills used (OBAG=98.3%, OBAC=97.1%, p=0.903). Finally, 110 patients completed their treatment and follow-up. They had a mean age of 40.57��12.74 years (range, 19-81 years). Fifty four (49.09%) patients were men. ITT and PP analyses showed similar eradication rate in both groups. According to the PP analysis, the success rates of eradication of H.pylori infection were 67.2% and 72.7% for OBAC and OBAG groups, respectively (p=0.568, table 1). Table 1 Demographic data and treatment results in patients receiving OBAC and/or OBAG There was significant statistical difference in the eradication rate of H.pylori infection according to the pathological findings between the two groups (p=0.001, table 2).</div>
77 underwent endoscopy and were diagnosed by using RUT and/or histological evaluation (64.1%), and 43 were diagnosed by UBT (35.9%). Endoscopy was performed by the discretion of the managing physician. A trained interviewer obtained demographic data and filled a standardized questionnaire. The participants were randomly assigned into two groups to receive OBAG or OBAC. The former group received omeprazole (20 mg) twice daily, bismuth subcitrate (240 mg) twice daily,
amoxicillin (1 gr) twice daily, and gemifloxacin (320 mg) once daily for 10 days, and the latter group received omeprazole (20 mg) twice daily, bismuth subcitrate (240 mg) twice daily, amoxicillin (1 gr) twice daily, and clarithromycin (500 mg) twice daily for 10 days. The participants were requested to refer again to the clinic during the second week to evaluate their compliance, as well as adverse drug effects. Compliance was Ro3280 acceptable when over 80% of the total medications were taken. The adverse effects included anorexia, nausea, vomiting, headache, skin rash, and bitter mouth. All the participants underwent UBT 8 weeks after completion of treatment to confirm H.pylori eradication. Gender distribution as well as the efficacy and frequency of side effects Erastin cell line in the two groups were compared by Chi-square test. Data analysis was performed on both per protocol (PP) and intention-to-treat (ITT) bases.
A p-value<0.05 was considered as statistically significant. Statistical analyses were performed using the SPSS software (version18; SPSS Inc.). This study was approved by both the Deputy Research of Iran University of Medical Sciences and Colorectal Research Center at Rasoul-e-Akram General Hospital, Tehran, Iran. RESULTS A total of 120 patients were enrolled in the study, and randomly assigned into OBAG (n=60) or OBAC (n=60) groups. Five patients from each group were excluded from the study because of poor compliance. Both groups had similar compliance according to the number of pills used (OBAG=98.3%, OBAC=97.1%, p=0.903). Finally, 110 patients completed their treatment and follow-up. They had a mean age of 40.57��12.74 years (range, 19-81 years). Fifty four (49.09%) patients were men. ITT and PP analyses showed similar eradication rate in both groups. According to the PP analysis, the success rates of eradication of H.pylori infection were 67.2% and 72.7% for OBAC and OBAG groups, respectively (p=0.568, table 1). Table 1 Demographic data and treatment results in patients receiving OBAC and/or OBAG There was significant statistical difference in the eradication rate of H.pylori infection according to the pathological findings between the two groups (p=0.001, table 2).</div>